639 patents
Page 2 of 32
Utility
Combination Therapy with Anti-pvrig Antibodies Formulations, Anti-tigit Antibodies, and ANTI-PD-1 Antibodies
16 Nov 23
The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
Adeboye Henry ADEWOYE, MD, Inbal BARBIRO, Ilan VAKNIN, Eran OPHIR, Pierre FERRE
Filed: 30 Sep 21
Utility
Macrocyclic Peptide Boronate Immunomodulators
16 Nov 23
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Tao WANG
Filed: 1 Oct 21
Utility
Immunostimulatory Agonistic Antibodies for Use In Treating Cancer
9 Nov 23
Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%.
Marie-Claude GAUDREAU, Chan GAO, Michael QUIGLEY, Praveen AANUR
Filed: 10 Mar 23
Utility
Methods for Increasing Productivity of Therapeutic Proteins
9 Nov 23
The present invention generally relates to a method of producing a therapeutic protein of interest secreted from host cells cultured in a bioreactor through adding a carboxypeptidase to the cell culture.
Jianlin XU, Shun ZHENG, Zeinab H Dawood
Filed: 21 Sep 21
Utility
Synthesis of 1,2,5-TRI-O-BENZOYL-3-DIBENZYLAMINO-3-DEOXYRIBOSE As Intermediate for Producing 3'-AMINO-3'-DEOXYADENOSINE and 3'-AMINO-3'-DEOXYGUANOSINE and the Protected Derivatives Thereof
9 Nov 23
The invention generally relates to improved processes for the preparation of intermediates of a cyclic dinucleotide which is useful as a STING agonist.
Changxia Yuan, Michael Anthony Schmidt, Adrian Ortiz, Amanda J. Rogers, Jason J. Zhu, Zhongmin Xu, Miao Yu, Eric M. Simmons, Shulin Wu
Filed: 5 Feb 20
Utility
Polymorphs of BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE Compounds and Uses Thereof
9 Nov 23
Marta DABROS, Joshua ENGSTROM, Daniel Richard ROBERTS
Filed: 2 Sep 21
Utility
FGF-21 Conjugate Formulations
2 Nov 23
The present application provides pharmaceutical formulations comprising PEGylated FGF−21, e.g., a FGF-21 conjugate, and one or more stabilizers such as the chelator DPTA.
Thomas PALM, Mehrnaz KHOSSRAVI, Sanket PATKE
Filed: 7 Jan 21
Utility
NLRP3 Modulators
2 Nov 23
Scott Hunter Watterson, Hua Gong, Kristin Williams, Ashvinikumar V. Gavai, Prasanna Sivaprakasam, Yong Zhang
Filed: 8 Jan 21
Utility
Oxopyrrolidine FPR2 Agonists
2 Nov 23
Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Amit Kumar Chattopadhyay, Balaji Seshadri, Vishweshwaraiah Baligar, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
Filed: 8 Jul 21
Utility
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
2 Nov 23
Matthew COX, Naidu S. CHOWDARI, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Christine M. TARBY, Yam B. POUDEL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
Filed: 26 Jan 21
Utility
Plug-and-analyze Framework for Knowledge Base Construction
26 Oct 23
Provided herein are system, apparatus, device, method, and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for generating a knowledge base.
Octavian Florin FILOTI, Christian Joseph MERRILL, Mark SALACINSKI, Irene Yue-Ling PAK
Filed: 20 Apr 22
Utility
Treatment of Cancer with TOR Kinase Inhibitors
26 Oct 23
Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer.
Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla
Filed: 28 Oct 22
Utility
Framework for Document Layout and Information Extraction
26 Oct 23
Provided herein are system, apparatus, device, method, and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for extracting data from a file.
Mark SALACINSKI, Christian Joseph Merrill, Octavian Florin Filoti, Irene Yue-Ling Pak
Filed: 20 Apr 22
Utility
Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists
26 Oct 23
Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
Filed: 22 May 23
Utility
Uracil Derivatives As Mer-axl Inhibitors
26 Oct 23
The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Christine M. Tarby, Derek J. Norris, Julian C. Lo, Vijay T. Ahuja, Steven P. Seitz, Ashvinikumar V. Gavai, John S. Tokarski, Mohini Rajasagi, Michael Wichroski, Matthias Broekema
Filed: 2 May 19
Utility
Transforming Growth Factor Beta (Tgfbeta) Binding Agents and Uses Thereof
26 Oct 23
There are provided tetravalent TGFβ receptor-ectodomain based traps having a tailored isoform-specificity profile for neutralization of TGFβ ligands, and methods of use thereof in the treatment of diseases and conditions associated with TGFβ, particularly TGFβ1 and TGFβ3.
Maureen O’Connor, Gilles Tremblay, Jean-Francois Denis, Vannakambadi K. Ganesh
Filed: 11 Jun 21
Utility
Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies
19 Oct 23
A method of treating an autoimmune disease such as Sjögren's Syndrome is provided.
Ying Ye, Urvi Aras, Nidhi Sharda, Mary Struthers, Karen Price, Ihab Girgis, Aberra Fura
Filed: 25 Aug 21
Utility
GSPT1 Compounds and Methods of Use of the Novel Compounds
19 Oct 23
Joshua Hansen, Mimi L. Quan
Filed: 13 Apr 23
Utility
Antagonistic CD40 Monoclonal Antibodies and Uses Thereof
12 Oct 23
The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains.
Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
Filed: 10 Mar 23
Utility
Substituted Heteroaryl Compounds Useful As Inhibitors of TLR9
12 Oct 23
Chunjian Liu, Alicia Regueiro-Ren
Filed: 18 Aug 21